Labskin (Innovenn Ltd.), a wholly-owned subsidiary of Integumen plc., (AIM:SKIN) today announces that it has entered into a partnership with RinoLab to provide Labskin clients with access to an AI machine learning platform which accelerates development of cosmetics, skincare, woundcare, personal hygiene and pharmaceutical topical drug delivery products, and does not require animal testing. The service is expected to go live in Q4, 2018.
Clinical Validation Service
Labskin has also entered into a partnership agreement with AIM quoted Venn Life Sciences Holdings plc (“Venn”) to integrate clinical validation protocols into Labskin AI. This will provide certified “Clinically Tested”product claim services to brand owners and producers of most skin care products. – see related party transaction below.
Artificially Intelligent Labskin Service
Labskin AI is an AI-based laboratory-grown human-skin testing platform. It uses clinical trial test protocols and datasets, eliminating the need for animal testing completely for the development of all skin care products. The AI platform and physical Labskin laboratories offer clients an online end to end skin care product validation system, tested on laboratory-grown human skin.
Labskin is Expanding
Due to the recent increase in demand for Labskin services, additional laboratory development support services are being provided through an agreement signed with Sheffield Hallam University, UK.
Gerard Brandon (CEO of Integumen plc and Director of Innovenn Ltd) commented:
“We are delighted to announce this collaboration of technologies and work with the skills and expertise of the RinoLab Team on the Labskin AI platform. Partnering with Venn Life Sciences and their clinical research organisation raises the bar for manufacturers of skin care products in quality control for consumer product information file (PIF) verification. Sheffield Hallam University has worked with Innovenn for many years in multiple Labskin development projects and extends the reach of our development services for our clients. Labskin has successfully moved from selling Labskin equipment supplies to being a fully fledged service provider during H2 2018, increasing our orders by 350% over H1. I believe that Labskin AI is now the ultimate go-to-market service for skin care product development, comprising formulation efficacy, testing and certification for EU and US consumer product launches.”
Tony Richardson (CEO Venn Life Sciences Holdings plc) commented:
“This is an exciting development and extends our pharmaceutical clinical validation approach to the consumer health, personal and skin care industries in a way that has never been done before. We see multiple opportunities for cross selling of services to the same clients of both Venn and Labskin, not least the new services of topical drug delivery and drug metabolism through the skin. By partnering with Labskin and RinoLab using the AI platform we look forward to being able to offer a unique certification service to Labskin clients, as well as extend AI machine learning data analysis across our CRO service to pharmaceutical clients, helping them reduce their overall development costs by getting their products to the market faster.”
Fin Murray (CEO of RinoCloud Ltd – RinoLab) commented:
“The RinoLab Team have developed a range of algorithms for the dissimination of big data specifically from scientific sources and is perfectly suited to analysing Labskin data to unlock trends and patterns that would normally be missed on a manual review. Using RinoLab, Labskin AI clients are provided with suggested alterations to improve product formulations to increase efficiency and efficacy. RinoLab analysis provides supporting data for the “Product Information File” required by cosmetic brand and skin care companies, prior to product launches in the US and EU markets.
Labskin (Innovenn Ltd – Integumen plc)
Laboratory-grown human skin testing services. Specifically developed to host harmful bacteria on simulated human skin. It is the best testing platform for antimicrobial products, such as anti-dandruff shampoos and anti-acne creams, anti-aging, anti-fungal, UV sun exposure, toxic shock, and drug delivery through the skin, which cannot currently be carried out in vivo (animal models) due to ethical constraints of testing harmful bacteria.
RinoLab (RinoCloud Ltd)
Rinolab is a set of software tools that ingests data from any source, in any format, interacts with it, learns from it and enriches it to unlock insights and discoveries. RinoLab is developed by Rinocloud Ltd, a company focused on delivering big data type functionality, AI functionality and world-class data management infrastructure.
Venn Life Sciences Holdings plc
Drug Development Partner
Venn Life Sciences Holdings plc is an Integrated Drug Development Partner offering a unique combination of drug development expertise, clinical trial design, and execution services. With more than 170 professionals Venn creates, plans and executes drug and medical device development programs effectively and seamlessly for their pharmaceutical manufacturing clients. With dedicated operations in Ireland, France, Germany, the Netherlands, the UK, the US, and Europe-wide representation.
In-vitro models are important tools for biological research and cell-based assays are used to predict drug activity, metabolism, and toxicity in-vivo. 2D monolayer culture systems in vitro tools are a typical tool used within the pharmaceutical industry at...
World Psoriasis Day, October 29th 2018. As much as 2-3% of the world’s population is currently suffering from psoriasis or some form of eczema such as atopic dermatitis. 1 in 5 children around the world has eczema. Currently, there is a lot of research...
Innovenn are looking for new team members, to enable us to expand our testing services for customers wanting to use Labskin for their testing regimes. The roles are: Operations Manager, tasked with the efficient day to day running of the...
Innovenn are pleased to announce that a new paper in the Journal of Proteomics has been released. Written by our partners at Sheffield Hallam University. Mass Spectrometry Imaging of 3D Tissue Models Cristina Russo, Emily E. L. Lewis, Lucy Flint, Malcolm R. Clench A...
Emily Lewis, part of the Labskin Research Team has been nominated for her research project developing a wound model using LABSKIN to conduct research and evaluate the healing process. You can vote for Emily with the following link - VOTE FOR EMILY! Thank you.
Well done to Emily Lewis who recently won the award for best presentation at Sheffield Hallum's KTP Day. Emily presented her work on developing a wound model using LABSKIN to conduct research and evaluate the healing process. Emily (second from left) is seen here with...
Phenotox Ltd, Innovenn Ltd, Manchester University Pharmacy School and Sheffield Hallam University Biomedical Research Centre and have been awarded Phase 1 funding from the UK-based National Centre for the Replacement, Refinement and Reduction of Animals in Research...
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that its innovation division, Innovenn, has commenced...